Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Insuman Comb 15 100 IU/ml suspension for injection in a vial Insuman Comb 15 100 IU/ml suspension for injection in a cartridge Insuman Comb 15 SoloStar 100 IU/ml suspension for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 39
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e.g. in oral contraceptives),
phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine
[adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 18919877bb39ad0d4ea769fe50ee0dec48b2e438f4ee9db39eb8acbd3926e791 · Zeichen 100–890 im Abschnitt
Wechselwirkungen · Apidra
Apidra 100 Units/ml solution for injection in a vial Apidra 100 Units/ml solution for injection in a cartridge Apidra SoloStar 100 Units/ml solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 5–6
5
Substances that may enhance the blood-glucose-lowering activity and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors (MAOIs), pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Substances that may reduce the blood-glucose-lowering activity include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic
medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones,
oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic
medicinal products (e.g. olanzapine and clozapine).
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the
blood-glucose-lowering activity of insulin. Pentamidine may cause hypoglycaemia, which may
sometimes be followed by hyperglycaemia.
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine,
guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-03-05T10:29:00Z · SHA-256 fc7e65813a72a5fb5b10ba10898c4aef13a83c5955dfc98f08190846113082bd · Passage 661b2a3146139e13085dd5957710df1feb005d83c38b437fd29b69c7627db493 · Zeichen 390–1603 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.